William Carson, III E MD

William Carson, III E MD
ProfessorCollege of Medicinecarson.77@osu.eduwebsite
N911 Doan Hall 410 W 10th Avenue Columbus Ohio 43210
Phone:614-293-6306Fax: (614) 293-3465
  • Translational Therapeutics

General Research Interest

Tumor immunology

Research Description

Dr. Carson is a surgical oncologist with clinical interests in breast cancer, melanoma and general cancer surgery. His primary research focus is the immunotherapy of tumors, which can be thought of as using drugs and other treatments to boost the human immune system's innate ability to fight tumor cells. Dr. Carson has a number of active cancer research grants which look at novel immunological approaches to the treatment of advanced malignant melanoma, the most deadly form of skin cancer.

Transinstitutional Work

Dr. Carson collaborates with OSU investigators who are investigating the effects of stress on immunity, nanotechnology for caner therapy, and the personalized use experimental therapeutics. He is active in the Society for Immunotherapy of Cancer and serves on the NCCN (National Comprehensive Cancer Network) advisory board for Melanoma. Dr. Carson is currently Vice Chair of the SWOG Melanoma Committee and he is on the NCCN Board of Directors. He also serves on the NCI IRG Subcommittee A that oversees the certification of Cancer Centers in the United States.

Current Publications

  • Carson WE, Farrar WB, Malarkey WB, Chen M, Kiecolt-Glaser JK, Fagundes CP, Jaremka LM, Glaser R, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Yee LDAttachment anxiety is related to Epstein-Barr virus latency.Brain Behav Immun in press 6/16/2014
  • Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, McMillian NR, Ho MMelanoma, version 4.2014.J Natl Compr Canc Netw 12 621-9 5/1/2014
  • Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Bloomfield CD, de la Chapelle A, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci GIntronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.Sci Signal 7 ra36 4/15/2014
  • Carson WE, Trikha PSignaling pathways involved in MDSC regulation.Biochim Biophys Acta in press 55-65 4/13/2014
  • Jaremka LM, Peng J, Bornstein R, Alfano CM, Andridge RR, Povoski SP, Lipari AM, Agnese DM, Farrar WB, Yee LD, Carson WE, Kiecolt-Glaser JKCognitive problems among breast cancer survivors: loneliness enhances risk.Psychooncology in press 4/11/2014
  • Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE, Tahiri S, Bhinder A, Clinton SK, Olencki TA phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.J Immunother 37 180-6 4/1/2014
  • Povoski SP, Lipari AM, Agnese DM, Hughes S, Jaremka LM, Alfano CM, Glaser R, Farrar WB, Yee LD, Carson WE, Malarkey WB, Kiecolt-Glaser JKSocial support predicts inflammation, pain, and depressive symptoms: longitudinal relationships among breast cancer survivors.Psychoneuroendocrinology 42 38-44 4/1/2014
  • Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle ANRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.Proc Natl Acad Sci U S A 111 4179-84 3/18/2014
  • Gray MR, Martin del Campo S, Zhang X, Zhang H, Souza FF, Carson WE, Smith ADMetastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.Radiology 270 425-34 2/1/2014
  • Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WEA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.J Immunother 37 55-62 1/1/2014
  • Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Bekaii-Saab T, Martin EW, Schmidt CR, Kiecolt-Glaser JKPain, Depression, and Fatigue: Loneliness as a Longitudinal Risk Factor.Health Psychol in press 8/19/2013
  • Lindgren ME, Fagundes CP, Alfano CM, Povoski SP, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE, Schmidt CR, Kiecolt-Glaser JKBeta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients.Psychooncology 22 1889-94 8/1/2013
  • Brooks TR, Carson WE, Markowitz J, Wesolowski R, Papenfuss TMyeloid-derived suppressor cells in breast cancer.Breast Cancer Res Treat 140 13-21 7/1/2013
  • Shin DJ, Park JY, Jang YY, Lee JJ, Lee YK, Shin MG, Jung JY, Carson WE, Cho D, Kim SKEx vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.Vet Immunol Immunopathol 153 249-59 6/15/2013
  • Matthews MA, Watkins D, Darbyshire A, Carson WE, Besner GEHeparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury.J Pediatr Surg 48 1316-22 6/1/2013
  • Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M, National Comprehensive Cancer Network (NCCN)Melanoma, version 2.2013: featured updates to the NCCN guidelines.J Natl Compr Canc Netw 11 395-407 4/1/2013
  • Markowitz J, Carson WEReview of S100A9 biology and its role in cancer.Biochim Biophys Acta 1835 100-9 1/1/2013
  • Liu Z, Yu J, Carson WE, Bai XFThe role of IL-27 in the induction of anti-tumor cytotoxic T lymphocyte response.Am J Transl Res 5 470-80 1/1/2013
  • Foy KC, Miller MJ, Moldovan N, Carson WE, Kaumaya PPCorrection to: Foy KC, Miller MJ, Moldovan N, Carson III WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1:1048-1060.Oncoimmunology 2 e23914 1/1/2013
  • Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson ABPostoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis.J Clin Oncol 31 30-8 1/1/2013
  • Tarr AJ, Powell ND, Reader BF, Bhave NS, Roloson AL, Carson WE, Sheridan JFβ-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption.Brain Behav Immun 26 1226-38 11/1/2012
  • Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PTCombined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Oncoimmunology 1 1048-1060 10/1/2012
  • Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PTImmunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.Oncoimmunology 1 1004-1016 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu